Bio-Rad Laboratories, Inc.(BIO)Earnings, Financials & Key Ratios

BIO•NYSE

$259.02

$6.99B mkt cap·9.3× P/E·Price updated May 6, 2026

SectorHealthcare IndustryMedical Devices Sub-IndustryDevice suppliers, distribution, and services

AboutBio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.Show more

Revenue$2.58B+0.7%
EBITDA$476M+13.1%
Net Income$760M+141.2%
EPS (Diluted)27.87+142.6%
Gross Margin52.01%-3.2%
EBITDA Margin18.42%+12.4%
Operating Margin10.47%
Net Margin29.42%+140.9%
ROE10.84%+145.0%
ROIC2.55%+8.7%
Debt/Equity0.21-1.8%
Interest Coverage5.52+111.8%

Technical→

BIO Key Insights

Bio-Rad Laboratories, Inc. (BIO) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Share count reduced 3.3% through buybacks
✓Trading at only 0.9x book value

✗Weaknesses

✗Profits declining 27.6% over 5 years
✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

BIO Price & Volume

Bio-Rad Laboratories, Inc. (BIO) stock price & volume — 10-year historical chart

Loading chart...

BIO Growth Metrics

Bio-Rad Laboratories, Inc. (BIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years2.49%

5 Years0.29%

3 Years-2.68%

TTM1.92%

Profit CAGR

10 Years20.99%

5 Years-27.58%

3 Years-

TTM107.8%

EPS CAGR

10 Years22.34%

5 Years-26.07%

3 Years-

TTM107.97%

Return on Capital

10 Years2.53%

5 Years2.96%

3 Years2.73%

Last Year2.85%

BIO Recent Earnings

Bio-Rad Laboratories, Inc. (BIO) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 8/12 qtrs (67%)●Beat Revenue 4/12 qtrs (33%)

Q2 2026Latest

Apr 30, 2026

EPS

$1.89

Est $1.97

-4.1%

Revenue

$592M

Est $590M

+0.4%

Q1 2026

Feb 12, 2026

EPS

$2.51

Est $2.57

-2.3%

Revenue

$693M

Est $689M

+0.6%

Q4 2025

Oct 29, 2025

EPS

$2.26

Est $2.30

-1.7%

Revenue

$653M

Est $695M

-6.0%

Q3 2025

Jul 31, 2025

EPS

$2.61

Est $1.93

+35.2%

Revenue

$652M

Est $634M

+2.8%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	Apr 30, 2026	$1.89vs $1.97-4.1%	$592Mvs $590M+0.4%
Q1 2026	Feb 12, 2026	$2.51vs $2.57-2.3%	$693Mvs $689M+0.6%
Q4 2025	Oct 29, 2025	$2.26vs $2.30-1.7%	$653Mvs $695M-6.0%
Q3 2025	Jul 31, 2025	$2.61vs $1.93+35.2%	$652Mvs $634M+2.8%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
TMOThermo Fisher Scientific Inc.Direct Competitor	175.76B	472.95	26.66	3.91%	15.18%	13.23%	0.76
DHRDanaher CorporationDirect Competitor	123.8B	174.92	34.71	2.9%	14.89%	7.06%	0.35
BRKRBruker CorporationDirect Competitor	6.44B	42.30	-282	2.08%	-0.75%	-1.11%	0.81
RGENRepligen CorporationDirect Competitor	7.09B	125.76	146.23	16.36%	6.73%	2.46%	0.33
CRLCharles River Laboratories International, Inc.Direct Competitor	8.97B	181.73	-62.45	-0.85%	-3.59%	-4.34%	0.95
IDXXIDEXX Laboratories, Inc.Product Competitor	46.12B	579.23	44.28	10.42%	24.63%	70.87%	0.67
HOLXHologic, Inc.Product Competitor	16.97B	76.01	30.53	1.74%	13.18%	10.37%	0.52
QGENQiagen N.V.Product Competitor	7.1B	34.46	16.89	5.65%	20.33%	11.85%	0.44

Compare BIO vs Peers

Bio-Rad Laboratories, Inc. (BIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs TMO

Most directly comparable listed peer for BIO.

Scale Benchmark

vs DHR

Larger-name benchmark to compare BIO against a more recognizable public peer.

Peer Set

Compare Top 5

vs TMO, DHR, BRKR, RGEN

BIO Income Statement

Bio-Rad Laboratories, Inc. (BIO) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Sales/Revenue	2.16B	2.29B	2.31B	2.55B	2.92B	2.8B	2.67B	2.57B	2.58B	2.59B
Revenue Growth %	4.45%	6.02%	0.94%	10.12%	14.81%	-4.12%	-4.67%	-3.92%	0.65%	1.92%
Cost of Goods Sold	972.75M	1.07B	1.05B	1.11B	1.28B	1.23B	1.24B	1.19B	1.24B	1.25B
COGS % of Revenue	45.03%	46.54%	45.62%	43.52%	43.95%	44.07%	46.58%	46.27%	47.99%	-
Gross Profit	1.19B▲ 0%	1.22B▲ 3.1%	1.26B▲ 2.7%	1.44B▲ 14.4%	1.64B▲ 13.9%	1.57B▼ 4.3%	1.43B▼ 9.0%	1.38B▼ 3.4%	1.34B▼ 2.6%	1.34B▲ 0%
Gross Margin %	54.97%	53.46%	54.38%	56.48%	56.05%	55.93%	53.42%	53.73%	52.01%	51.87%
Gross Profit Growth %	4.33%	3.11%	2.67%	14.39%	13.92%	-4.32%	-8.96%	-3.37%	-2.56%	-
Operating Expenses	1.06B	1.03B	1.03B	1.02B	1.14B	1.08B	1.09B	1.11B	1.08B	1.1B
OpEx % of Revenue	49.04%	45.08%	44.44%	39.93%	38.93%	38.71%	40.77%	43.25%	41.71%	-
Selling, General & Admin	808.94M	833.29M	824.63M	798.8M	877.12M	827.83M	841.7M	814M	819.9M	843.5M
SG&A % of Revenue	37.45%	36.39%	35.67%	31.38%	30.01%	29.54%	31.51%	31.72%	31.74%	-
Research & Development	250.3M	199.2M	202.71M	217.76M	260.64M	256.89M	247.43M	295.9M	256.9M	260.4M
R&D % of Revenue	11.59%	8.7%	8.77%	8.55%	8.92%	9.17%	9.26%	11.53%	9.95%	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income	116.65M▲ 0%	-108.64M▼ 193.1%	229.66M▲ 311.4%	421.33M▲ 83.5%	500.34M▲ 18.8%	482.62M▼ 3.5%	337.8M▼ 30.0%	269M▼ 20.4%	270.5M▲ 0.6%	239.5M▲ 0%
Operating Margin %	5.4%	-4.74%	9.93%	16.55%	17.12%	17.22%	12.65%	10.48%	10.47%	9.25%
Operating Income Growth %	119.29%	-193.13%	311.39%	83.46%	18.75%	-3.54%	-30.01%	-20.37%	0.56%	-
EBITDA	265.35M	29.46M	404.16M	559.93M	637.94M	659.82M	483.7M	420.6M	475.9M	-314.9M
EBITDA Margin %	12.28%	1.29%	17.48%	22%	21.83%	23.55%	18.11%	16.39%	18.42%	-12.16%
EBITDA Growth %	35.32%	-88.9%	1271.94%	38.54%	13.93%	3.43%	-26.69%	-13.04%	13.15%	-173.05%
D&A (Non-Cash Add-back)	148.7M	138.1M	174.5M	138.6M	137.6M	177.2M	145.9M	151.6M	205.4M	157.2M
EBIT	120.82M	536.62M	2.28B	4.94B	5.45B	-4.67B	-800.66M	-2.29B	270.5M	-122.6M
Net Interest Income	-3.91M	2.64M	7.08M	-3.66M	17.35M	19.89M	51.46M	33.1M	46.5M	10.1M
Interest Income	19.1M	26.6M	30.5M	18.2M	18.9M	58M	100.9M	82M	95.5M	59.4M
Interest Expense	23.01M	23.96M	23.42M	21.86M	1.55M	38.11M	49.44M	48.9M	49M	49.3M
Other Income/Expense	-15.35M	319.39M	2.03B	4.5B	4.95B	-5.19B	-1.19B	-2.61B	725M	-17.2M
Pretax Income	97.81M▲ 0%	507.36M▲ 418.7%	2.26B▲ 345.7%	4.92B▲ 117.5%	5.45B▲ 10.8%	-4.7B▼ 186.3%	-850.1M▲ 81.9%	-2.34B▼ 175.6%	995.5M▲ 142.5%	222.3M▲ 0%
Pretax Margin %	4.53%	22.15%	97.81%	193.19%	186.45%	-167.87%	-31.82%	-91.27%	38.54%	8.58%
Income Tax	-16.93M	146.36M	502.41M	1.1B	1.19B	-1.08B	-212.78M	-498.3M	235.6M	53.5M
Effective Tax Rate %	-17.32%	28.85%	22.22%	22.44%	21.93%	22.89%	25.03%	21.27%	23.67%	24.07%
Net Income	114.74M▲ 0%	361M▲ 214.6%	1.76B▲ 387.2%	3.81B▲ 116.9%	4.25B▲ 11.5%	-3.63B▼ 185.3%	-637.32M▲ 82.4%	-1.84B▼ 189.4%	759.9M▲ 141.2%	168.8M▲ 0%
Net Margin %	5.31%	15.76%	76.08%	149.83%	145.57%	-129.45%	-23.86%	-71.86%	29.42%	6.52%
Net Income Growth %	307.96%	214.62%	387.17%	116.88%	11.54%	-185.27%	82.43%	-189.37%	141.2%	107.8%
Net Income (Continuing)	122.25M	365.61M	1.76B	3.81B	4.25B	-3.63B	-637.32M	-1.84B	759.9M	168.8M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)	4.07▲ 0%	11.94▲ 193.4%	58.27▲ 388.0%	126.20▲ 116.6%	140.83▲ 11.6%	-121.79▼ 186.5%	-21.82▲ 82.1%	-65.36▼ 199.5%	27.87▲ 142.6%	6.26▲ 0%
EPS Growth %	362.5%	193.37%	388.02%	116.58%	11.59%	-186.48%	82.08%	-199.54%	142.64%	107.97%
EPS (Basic)	4.12	12.10	58.93	127.86	142.61	-121.79	-21.82	-65.36	27.87	-
Diluted Shares Outstanding	30.03M	30.23M	30.18M	30.16M	30.21M	29.79M	29.21M	28.21M	27.28M	26.96M
Basic Shares Outstanding	29.66M	29.84M	29.84M	29.77M	29.83M	29.79M	29.21M	28.21M	27.26M	26.96M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

BIO Balance Sheet

Bio-Rad Laboratories, Inc. (BIO) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Total Current Assets	1.98B	2.02B	2.18B	2.14B	1.99B	3.16B	3.05B	3.03B	2.91B	0
Cash & Short-Term Investments	754.98M	844.8M	1.11B	991.12M	869.92M	1.79B	1.61B	1.66B	1.54B	0
Cash Only	383.82M	431.53M	660.67M	662.21M	470.78M	434.21M	403.8M	488.1M	531.8M	0
Short-Term Investments	371.15M	413.27M	453.97M	328.91M	399.13M	1.36B	1.2B	1.18B	1.01B	0
Accounts Receivable	464.85M	392.44M	392.67M	419.42M	423.54M	494.64M	489M	452.5M	472.5M	0
Days Sales Outstanding	78.55	62.55	62	60.14	52.9	64.43	66.82	64.35	66.76	49.91
Inventory	594.8M	583.82M	554.01M	622.25M	572.24M	719.32M	780.5M	760M	740.7M	0
Days Inventory Outstanding	223.18	199.95	191.73	205.03	162.61	212.61	228.95	233.58	218.1	170.02
Other Current Assets	15.88M	15.18M	16.5M	16.42M	15.65M	29.16M	31.7M	30.7M	13.8M	0
Total Non-Current Assets	2.3B	3.59B	5.83B	10.83B	15.81B	10.34B	9.25B	6.33B	7.67B	0
Property, Plant & Equipment	493.5M	508.69M	701.21M	693.51M	716.44M	679.55M	723.7M	688.6M	709.9M	0
Fixed Asset Turnover	4.38x	4.50x	3.30x	3.67x	4.08x	4.12x	3.69x	3.73x	3.64x	4.77x
Goodwill	506.1M	219.8M	264.1M	291.9M	347.3M	406.5M	413.6M	410.5M	579.8M	0
Intangible Assets	174.1M	133.1M	145.5M	199.5M	253.9M	332.1M	320.5M	293.6M	174.3M	0
Long-Term Investments	1.03B	2.66B	4.64B	9.56B	14.39B	8.83B	7.7B	4.84B	6.1B	16.74B
Other Non-Current Assets	94.95M	70.3M	79.64M	86.72M	104.19M	94.6M	94.9M	101.9M	102.3M	318.8M
Total Assets	4.27B▲ 0%	5.61B▲ 31.3%	8.01B▲ 42.7%	12.97B▲ 62.0%	17.8B▲ 37.2%	13.5B▼ 24.1%	12.3B▼ 8.9%	9.36B▼ 23.9%	10.58B▲ 12.9%	0▲ 0%
Asset Turnover	0.51x	0.41x	0.29x	0.20x	0.16x	0.21x	0.22x	0.27x	0.24x	0.34x
Asset Growth %	10.97%	31.31%	42.73%	61.98%	37.21%	-24.15%	-8.91%	-23.86%	12.95%	-90.18%
Total Current Liabilities	502.7M	450.8M	905.5M	631.54M	680.94M	568.71M	522.8M	467.8M	517M	917M
Accounts Payable	135.18M	122.45M	107.01M	139.45M	141.94M	135.04M	144.6M	122.3M	129M	133.1M
Days Payables Outstanding	50.72	41.94	37.04	45.95	40.34	39.91	42.42	37.59	37.98	38.81
Short-Term Debt	420K	493K	425.7M	1.3M	489K	465K	500K	1.2M	37.9M	436.7M
Deferred Revenue (Current)	28.23M	26.94M	33.73M	42.47M	50.85M	52.21M	0	0	0	0
Other Current Liabilities	127.29M	101.22M	86.81M	131.1M	127.94M	117.44M	161.6M	147.2M	141.2M	347.2M
Current Ratio	3.93x	4.49x	2.41x	3.39x	2.92x	5.55x	5.83x	6.48x	5.62x	5.62x
Quick Ratio	2.75x	3.19x	1.80x	2.40x	2.08x	4.29x	4.34x	4.85x	4.19x	4.19x
Cash Conversion Cycle	251.01	220.56	216.7	219.22	175.17	237.12	253.35	260.35	246.88	181.12
Total Non-Current Liabilities	840.07M	1.14B	1.35B	2.46B	3.43B	3.32B	3.04B	2.33B	2.61B	2.02B
Long-Term Debt	434.58M	438.94M	2.4M	1.3M	10.51M	1.2B	1.2B	1.2B	1.34B	138.6M
Capital Lease Obligations	0	0	187.22M	186.13M	175.94M	153.6M	165.5M	131.4M	154.4M	483.8M
Deferred Tax Liabilities	222.21M	553.24M	997.79M	2.08B	3.06B	1.77B	1.48B	818M	1.06B	3.77B
Other Non-Current Liabilities	183.28M	147.77M	160.9M	196.93M	182.19M	195.93M	195M	177.2M	53.4M	1.47B
Total Liabilities	1.34B	1.59B	2.25B	3.09B	4.11B	3.89B	3.56B	2.79B	3.12B	2.94B
Total Debt	435M	439.43M	651.18M	225.74M	223.38M	1.39B	1.41B	1.37B	1.53B	575.3M
Net Debt	51.18M	7.9M	-9.49M	-436.47M	-247.41M	953.88M	1B	886.6M	999.2M	575.3M
Debt / Equity	0.15x	0.11x	0.11x	0.02x	0.02x	0.14x	0.16x	0.21x	0.21x	0.21x
Debt / EBITDA	1.64x	14.92x	1.61x	0.40x	0.35x	2.10x	2.91x	3.27x	3.22x	-1.83x
Net Debt / EBITDA	0.19x	0.27x	-0.02x	-0.78x	-0.39x	1.45x	2.07x	2.11x	2.10x	2.10x
Interest Coverage	5.25x	22.39x	97.56x	225.97x	3514.25x	-122.43x	-16.20x	-46.90x	5.52x	-2.49x
Total Equity	2.93B▲ 0%	4.02B▲ 37.2%	5.76B▲ 43.1%	9.88B▲ 71.7%	13.69B▲ 38.5%	9.62B▼ 29.7%	8.74B▼ 9.1%	6.57B▼ 24.8%	7.45B▲ 13.5%	6.85B▲ 0%
Equity Growth %	13.61%	37.2%	43.15%	71.67%	38.52%	-29.74%	-9.09%	-24.85%	13.46%	11.17%
Book Value per Share	97.56	133.00	190.67	327.58	453.03	322.82	299.26	232.84	273.22	254.15
Total Shareholders' Equity	2.93B	4.02B	5.76B	9.88B	13.69B	9.62B	8.74B	6.57B	7.45B	6.85B
Common Stock	3K	3K	3K	3K	3K	3K	0	0	0	0
Retained Earnings	1.83B	3.72B	5.47B	9.27B	13.53B	9.9B	9.26B	7.42B	8.18B	7.65B
Treasury Stock	-217K	-49.13M	-38.4M	-99.91M	-106.29M	-263.59M	-632.5M	-772.1M	-1.01B	0
Accumulated OCI	738.79M	-46.96M	-87.35M	282.46M	-175.55M	-466.82M	-336M	-538.2M	-189.1M	-235.4M
Minority Interest	0	0	0	0	0	0	0	0	0	0

BIO Cash Flow Statement

Bio-Rad Laboratories, Inc. (BIO) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Cash from Operations	104.14M	285.49M	457.9M	584.97M	669.46M	194.45M	374.94M	455.2M	532.2M	532.2M
Operating CF Margin %	4.82%	12.47%	19.81%	22.98%	22.91%	6.94%	14.04%	17.74%	20.6%	-
Operating CF Growth %	-51.8%	174.15%	60.39%	27.75%	14.44%	-70.95%	92.83%	21.41%	16.92%	9.24%
Net Income	122.2M	365.6M	1.76B	3.81B	4.25B	-3.63B	-637.3M	-1.84B	759.9M	168.8M
Depreciation & Amortization	148.7M	138.1M	134.2M	138.6M	137.6M	137.3M	145.9M	151.6M	205.4M	68.5M
Stock-Based Compensation	23.4M	27.8M	35.6M	41.6M	51.2M	60.9M	61.3M	62.3M	0	-15.3M
Deferred Taxes	0	0	0	0	0	0	0	0	170.5M	101.8M
Other Non-Cash Items	13.54M	-323.01M	-2.03B	-4.5B	-4.92B	5.23B	1.24B	2.71B	-879.2M	-94.3M
Working Capital Changes	-203.7M	77M	555.9M	1.09B	1.14B	-1.61B	-432.8M	-620.8M	275.6M	202.7M
Change in Receivables	-64.1M	59.7M	1.6M	-15M	-20.4M	-87.4M	11.4M	16.2M	19.6M	-29.1M
Change in Inventory	-47.7M	-12.9M	24.2M	-52.1M	46.1M	-158.8M	-46.3M	8.5M	68.9M	83.1M
Change in Payables	7.8M	-45.6M	10.6M	124.7M	69.9M	-94.2M	-51.8M	-40.9M	-100K	-64.4M
Cash from Investing	-175.57M	-186.98M	-208.89M	-69.89M	-797.38M	-1.21B	20.21M	-160.2M	-189.7M	-285.8M
Capital Expenditures	-115.13M	-129.83M	-98.53M	-108.56M	-133.75M	-112.78M	-156.68M	-165.6M	-157.6M	-153.2M
CapEx % of Revenue	5.33%	5.67%	4.26%	4.26%	4.58%	4.02%	5.87%	6.45%	6.1%	-
Acquisitions	0	6.96M	-79.39M	-84.42M	-125.52M	-99.39M	2.5M	0	-218.4M	-218.4M
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-914K	4.32M	8.95M	3.48M	-453.39M	-1.21M	211K	-23.3M	793.6M	793.7M
Cash from Financing	341K	-48.68M	-22.76M	-523.04M	-55.43M	973.58M	-425.65M	-218.8M	-283.2M	-229.5M
Debt Issued (Net)	-352K	-2.96M	-643K	-426.94M	-3.02M	1.19B	-467K	-400K	-500K	-700K
Equity Issued (Net)	-2.92M	-48.91M	-28M	-100M	-50M	-215.68M	-428.73M	-203.6M	-279.7M	-182.1M
Dividends Paid	0	0	0	0	0	0	0	0	0	-33.3M
Share Repurchases	-2.92M	-48.91M	-28M	-100M	-50M	-215.68M	-428.73M	-203.6M	-295.5M	-241.4M
Other Financing	3.61M	3.19M	5.88M	3.9M	-2.41M	3.54M	3.55M	-14.8M	-3M	-13.4M
Net Change in Cash	-72.19M▲ 0%	49.18M▲ 168.1%	228.49M▲ 364.6%	4.46M▼ 98.0%	-195.98M▼ 4490.3%	-36.59M▲ 81.3%	-30.18M▲ 17.5%	85.4M▲ 383.0%	40.3M▼ 52.8%	-16.1M▲ 0%
Free Cash Flow	-10.99M▲ 0%	155.67M▲ 1516.4%	359.37M▲ 130.9%	476.41M▲ 32.6%	535.72M▲ 12.4%	80.29M▼ 85.0%	218.26M▲ 171.8%	266.2M▲ 22.0%	374.6M▲ 40.7%	357.2M▲ 0%
FCF Margin %	-0.51%	6.8%	15.55%	18.71%	18.33%	2.87%	8.17%	10.37%	14.5%	13.79%
FCF Growth %	-114.75%	1516.43%	130.86%	32.57%	12.45%	-85.01%	171.84%	21.96%	40.72%	7.56%
FCF per Share	-0.37	5.15	11.91	15.80	17.73	2.70	7.47	9.44	13.73	13.73
FCF Conversion (FCF/Net Income)	0.91x	0.79x	0.26x	0.15x	0.16x	-0.05x	-0.59x	-0.25x	0.70x	2.12x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

BIO Key Ratios

Bio-Rad Laboratories, Inc. (BIO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	4.17%	10.39%	35.98%	48.79%	36.11%	-31.14%	-6.94%	-24.09%	10.84%	2.4%
Return on Invested Capital (ROIC)	3.16%	-2.32%	3.52%	4.16%	3.28%	3.02%	2.49%	2.35%	2.55%	2.55%
Gross Margin	54.97%	53.46%	54.38%	56.48%	56.05%	55.93%	53.42%	53.73%	52.01%	51.87%
Net Margin	5.31%	15.76%	76.08%	149.83%	145.57%	-129.45%	-23.86%	-71.86%	29.42%	6.52%
Debt / Equity	0.15x	0.11x	0.11x	0.02x	0.02x	0.14x	0.16x	0.21x	0.21x	0.21x
Interest Coverage	5.25x	22.39x	97.56x	225.97x	3514.25x	-122.43x	-16.20x	-46.90x	5.52x	-2.49x
FCF Conversion	0.91x	0.79x	0.26x	0.15x	0.16x	-0.05x	-0.59x	-0.25x	0.70x	2.12x
Revenue Growth	4.45%	6.02%	0.94%	10.12%	14.81%	-4.12%	-4.67%	-3.92%	0.65%	1.92%

BIO SEC Filings & Documents

Bio-Rad Laboratories, Inc. (BIO) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Apr 30, 2026·SEC

Material company update

Apr 24, 2026·SEC

Material company update

Feb 19, 2026·SEC

10-K Annual Reports

FY 2026

Feb 13, 2026·SEC

FY 2025

Feb 14, 2025·SEC

FY 2024

Feb 16, 2024·SEC

10-Q Quarterly Reports

FY 2026

Apr 30, 2026·SEC

FY 2025

Oct 29, 2025·SEC

FY 2025

Jul 31, 2025·SEC

BIO Frequently Asked Questions

Bio-Rad Laboratories, Inc. (BIO) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Bio-Rad Laboratories, Inc. (BIO) reported $2.59B in revenue for fiscal year 2025. This represents a 518% increase from $418.8M in 1996.

Bio-Rad Laboratories, Inc. (BIO) grew revenue by 0.7% over the past year. Growth has been modest.

Yes, Bio-Rad Laboratories, Inc. (BIO) is profitable, generating $168.8M in net income for fiscal year 2025 (29.4% net margin).

Dividend & Returns

Bio-Rad Laboratories, Inc. (BIO) has a return on equity (ROE) of 10.8%. This is reasonable for most industries.

Bio-Rad Laboratories, Inc. (BIO) generated $357.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More BIO

Bio-Rad Laboratories, Inc. (BIO) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Bio-Rad Laboratories, Inc.(BIO)Earnings, Financials & Key Ratios

BIO Key Insights

✓Strengths

✗Weaknesses

BIO Price & Volume

BIO Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

BIO Recent Earnings

BIO Peer Comparison

Compare BIO vs Peers

vs TMO

vs DHR

Compare Top 5

BIO Income Statement

BIO Balance Sheet

BIO Cash Flow Statement

BIO Key Ratios

BIO SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

BIO Frequently Asked Questions

Explore More BIO

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation